3 Excipients and Food Ingredients, Domestic Volume Leader and Paracetamol Ingredients Stocks With a Strong Future Roadmap: Sudeep Pharma, Mankind Pharma and Granules India
- October 22, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Sudeep Pharma, Mankind Pharma and Granules India: ROE of 11.7% to 19.6% and FY22 to FY26 revenue CAGR of 9.2% to 17.6%. Prices as of 21 Oct 2026.
Quick Answer
The three pharma ingredients and consumer health stocks to watch are Sudeep Pharma, Mankind Pharma and Granules India. Their return on equity ranges from 11.7% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 17.6%. Sudeep Pharma leads on both return on equity at 19.6% and revenue growth at 17.6% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.
Pharma ingredients and consumer health stocks let investors follow companies that supply inputs to drug makers and sell medicines and health brands to patients. Sudeep Pharma, Mankind Pharma and Granules India cover excipients and food ingredients, a domestic volume leader and paracetamol and other ingredients.
This list covers three pharma ingredients and consumer health stocks with complete current figures: Sudeep Pharma, Mankind Pharma and Granules India. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Ingredients and Consumer Health Stocks?
Pharma ingredients and consumer health stocks are listed companies that make excipients, active ingredients and finished medicines and consumer health brands. Their earnings depend on volume growth, customer contracts and brand strength.
Pharma Ingredients and Consumer Health Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Sudeep Pharma | 971.6 | 11,352 | 61.8 | 35.1 | 19.6 | 0.17 |
| Mankind Pharma | 2,285.5 | 93,014 | 45.0 | 36.0 | 11.7 | 0.39 |
| Granules India | 807.65 | 22,002 | 33.2 | 36.0 | 11.7 | 0.30 |
On valuation, Granules India trades at a P/E below the industry P/E, while Sudeep Pharma and Mankind Pharma trade above it, which reflects the growth the market already expects. Readers comparing pharma ingredients and consumer health stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pharma ingredients and consumer health stocks can use the coming numbers to test whether growth is holding.
Why Do Pharma Ingredients and Consumer Health Stocks Have a Strong Roadmap in India?
Pharma ingredients and consumer health stocks have a strong roadmap in India because rising medicine use, wider consumer health spending and growing global demand for ingredients support steady volumes.
- Rising medicine use. More patients and wider access lift volumes.
- Ingredient demand. Drug and food makers keep sourcing inputs from Indian plants.
- Consumer health. Branded health products draw repeat purchases.
Why Sudeep Pharma Features Among These Pharma Ingredients and Consumer Health Stocks
Among the pharma ingredients and consumer health stocks on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.
In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%.
Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.
Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
What to watch: Check capacity expansion progress and export revenue growth.
Why Mankind Pharma Features Among These Pharma Ingredients and Consumer Health Stocks
Among the excipient maker shares on this list, Mankind Pharma is one of India’s largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.
Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore.
Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
What to watch: Watch the market share in chronic therapies and the integration of acquired brands.
Why Granules India Features Among These Pharma Ingredients and Consumer Health Stocks
Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.
Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%.
In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.
Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What to watch: Monitor new product approvals and the share of finished dosages in total sales.
Sudeep Pharma vs Mankind Pharma vs Granules India on Key Financials
The table below sets the three pharma ingredients and consumer health stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Sudeep Pharma | 350 | 671 | 17.6% | 174 | 26.0% |
| Mankind Pharma | 7,978 | 14,636 | 16.4% | 1,938 | 13.2% |
| Granules India | 3,783 | 5,386 | 9.2% | 595 | 11.0% |
Sudeep Pharma posts the highest return on equity in this group at 19.6%. Mankind Pharma has the largest FY26 revenue at Rs 14,636 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with pharma ingredients and consumer health stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Sudeep Pharma | 130 | 164 | 25.9% |
| Mankind Pharma | 3,650 | 4,076 | 11.7% |
| Granules India | 1,226 | 1,479 | 20.6% |
Key Risks to Check Before Investing in Pharma Ingredients and Consumer Health Stocks
Every theme carries risks that deserve a check before any decision. For these pharma ingredients and consumer health stocks, the main points are: Long-term excipient maker shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Input costs. Prices of raw materials can affect margins.
- Competition. Many players compete in common ingredients and brands.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma ingredients and consumer health stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma Ingredients and Consumer Health Stocks
Pharma ingredients and consumer health stocks reward investors who follow volumes, capacity and margins together. Sudeep Pharma, Mankind Pharma and Granules India each address a different part of the health value chain. Based on the 21 October 2026 close, Sudeep Pharma trades at Rs 971.6, Mankind Pharma at Rs 2,285.5 and Granules India at Rs 807.65. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma ingredients and consumer health stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma ingredients and consumer health stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma ingredients and consumer health stocks?
Ans. Pharma ingredients and consumer health stocks are listed companies that make excipients, active ingredients and finished medicines and consumer health brands. Their earnings depend on volume growth, customer contracts and brand strength. This list looks at three of them, Sudeep Pharma, Mankind Pharma and Granules India, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.
Which pharma ingredients and consumer health stocks are covered in this list?
Ans. This list covers Sudeep Pharma, Mankind Pharma and Granules India. Based on the 21 October 2026 close, Sudeep Pharma traded at Rs 971.6, Mankind Pharma at Rs 2,285.5 and Granules India at Rs 807.65. Their return on equity ranges from 11.7% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 17.6%.
Why do pharma ingredients and consumer health stocks have a strong future roadmap in India?
Ans. Pharma ingredients and consumer health stocks have a strong roadmap in India because rising medicine use, wider consumer health spending and growing global demand for ingredients support steady volumes. The main drivers are as follows. Rising medicine use. More patients and wider access lift volumes. Ingredient demand. Drug and food makers keep sourcing inputs from Indian plants. Consumer health. Branded health products draw repeat purchases. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Sudeep Pharma performed financially?
Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
How has Mankind Pharma performed financially?
Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
How has Granules India performed financially?
Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What risks should investors check before buying pharma ingredients and consumer health stocks?
Ans. Investors should check a few risks before buying pharma ingredients and consumer health stocks. Input costs. Prices of raw materials can affect margins. Competition. Many players compete in common ingredients and brands. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma ingredients and consumer health stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
